Cancer Management and Research (Dec 2020)
Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment
Abstract
Xiao-Hong Xie,* Fei Wang,* Xin-Qing Lin, Yin-Yin Qin, Zhan-Hong Xie, Jie-Xia Zhang, Ming Ouyang, Cheng-Zhi Zhou State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of the Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, People’s Republic of China*These authors contributed equally to this workCorrespondence: Cheng-Zhi ZhouState Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of the Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of ChinaTel +86-20-83062830Email [email protected]: The study aimed to analyze the efficacy and safety of combination regimen of anlotinib and S-1 for Chinese patients with EGFR mutation-negative advanced squamous cell lung cancer (SqCLC) with poor performance status (PS,2– 3) after progression of second-line or later-line chemotherapy.Methods: Clinical data of 70 SqCLC patients with PS scores of 2– 3 treated in the First Affiliated Hospital of Guangzhou Medical University between January 1, 2018 to September 31, 2019 who failed second- or more-line treatment were analysed retrospectively. The patients were divided into two treatment groups: anlotinib (12mg) plus S-1 (25mg) combination group and anlotinib (12mg) monotherapy group. The efficacy and adverse reactions of the two groups were compared.Results: In terms of the short-term efficacy, there were no significant differences in objective response rate (ORR) (20.0% vs 10.0%, p = 0.464) and disease control rate (DCR) (75.0% vs 60.0%, p = 0.181) between the two groups. As for the long-term efficacy, there was no significant difference in progression-free survival (PFS) between the two groups (3.87± 0.29 months vs 3.00± 0.24 months, p=0. 11). The overall survival (OS) of patients in the combination group was longer than S1 group (8.07± 0.56 months vs 6.17± 0.42 months, p=0.022).Conclusion: Advanced SqCLC patients with higher PS scores still benefit from anlotinib and S-1 combination regimen, even after they failed second-line or later-line systemic treatment.Keywords: anlotinib, S-1, advanced squamous cell lung cancer, performance status, efficacy